Seegene and Samsung Medical Center to Develop MDx Tests for Cancer

Seegene will contribute its DPO and READ PCR technologies; while SMC will provide clinical and disease pathology expertise and the first test sites for the new assays.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.